ctl019 t-cells
B-Cell Acute Lymphoblastic Leukemia
Novartis PharmaceuticalsCell therapyPhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 73/ 100
Competitive context
141 Active assets in the B-Cell Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE University of Washington | Phase 3 | BBB |
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) City of Hope Medical Center | Phase 3 | BB |
VINCRISTINE SULFATE City of Hope Medical Center | Phase 3 | BB |
MERCAPTOPURINE ANHYDROUS SWOG Cancer Research Network | Phase 3 | BB |
Dasatinib National Cancer Institute (NCI) | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →